The role of CHKB in osteoclastic bone resorption and bone homeostasis

骨质疏松症是一种毁灭性的疾病。老年人骨质疏松性骨折与死亡率增加相关。仅骨质疏松症每年就花费138亿美元。在美国和澳大利亚的数千万美元。到2040年，仅因髋部骨折而致残的老龄人口给社会造成的损失就可能增加两倍。我们的研究检查了CHKB在骨丢失中的作用，这可能强调其作为抗吸收药物开发的新分子靶点的潜力。

Osteoporosis is a devastating disorder. Osteoporotic fractures in the elderly have been correlated with increased mortality rates. Osteoporosis alone costs $13.8 billion p.a. in USA and tens of millions of dollars in Australia. Cost to society of our ageing population for people become disabled by hip fractures alone could triple by the year 2040. Our research examines the role of CHKB in bone loss which may underscore its potential as a new molecular target for anti-resorptive drug development.